Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience

17 Aug 2018

Abstract excerpt

Replication-competent retrovirus (RCR) is a safety concern for individuals treated with retroviral gene therapy. RCR detection assays are used to detect RCR in manufactured vector, transduced cell products infused into research subjects, and in the research subjects after treatment. In this study, we reviewed 286 control (n = 4) and transduced cell products (n = 282) screened for RCR in the National Gene Vector...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30211249
DOI: 10.1016/j.omtm.2018.08.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository ExperiencePMID 30211249Read ↗

Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell ProductsSemantic proximity Read ↗

Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology PatientsSemantic proximity Read ↗

Replication-competent Lentivirus Analysis of Clinical Grade Vector ProductsSemantic proximity Read ↗

Regulatory Considerations for Novel Gene Therapy Products: A Review of the Process Leading to the First Clinical Lentiviral VectorSemantic proximity Read ↗

Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience.Semantic proximity Read ↗

A Guide to Approaching Regulatory Considerations for Lentiviral-Mediated Gene TherapiesSemantic proximity Read ↗

Lentiviral vector packaging and producer cell lines yield titers equivalent to the industry-standard four-plasmid processSemantic proximity Read ↗

Improved Methods of Retroviral Vector Transduction and Production for Gene TherapySemantic proximity Read ↗

Large-scale Clinical-grade Retroviral Vector Production in a Fixed-Bed BioreactorSemantic proximity Read ↗

Certification assays for HIV-1-based vectors: frequent passage of gag sequences without evidence of replication-competent virusesSemantic proximity Read ↗

Development of Lentiviral Packaging Cells and Scale Up of Production to Meet the Growing Demand in Cell and Gene TherapySemantic proximity Read ↗

Inadvertent Transfer of Murine VL30 Retrotransposons to CAR-T CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.